Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | Director | April 23, 2026 | April 27, 2026 |
| Scribe Therapeutics, Inc.SCTX · Entity 5494 | 10% owner | July 27, 2026 | July 29, 2026 |
| Tempus AI, Inc.TEM · Entity 1545 | Director | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 10,899.1714 |
Reported balance
After 2026-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 975 · Balance 10,899.1714 F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).
F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.
Scribe Therapeutics, Inc.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 603,547 |
Reported balance
After 2026-07-27 transaction · row 1
1 source rowRow 1 · 2026-07-27 · Conversion · Acquired 12,511 · Balance 603,547 F1: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-27 · Conversion · Disposed 74,088 · Balance 0 F1: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
Tempus AI, Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 25,266 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 676 · Balance 25,266 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:05 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 676 | $65.55 | $44,311.80 |
DisclosureSEC source: 0001739090-26-000012 · form4-09032026_040904.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,266 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2025. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:21 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | ConversionSeries A-1 Preferred Stock · Derivative | 74,088 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739090-26-000010 · form4-07292026_080745.xml · derivative · entry 2 Doudna Jennifer A · CIK 0001739090 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,511 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date. F1 · price: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:21 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | ConversionCommon Stock | 12,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739090-26-000010 · form4-07292026_080745.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date. Read SEC document |
| June 25, 2026 Filed Jun 30, 2026 00:40 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 2,673 | $55.00 | $147,015.00 |
DisclosureSEC source: 0001739090-26-000006 · form4-06292026_080604.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,942 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2025. Read SEC document |
| May 21, 2026 Filed May 27, 2026 01:45 UTC | Tempus AI, Inc. TEM · Entity 1545 | GrantClass A Comnmon Stock | 5,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001739090-26-000004 · form4-05262026_090504.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,615 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the Issuer's 2027 annual meeting of the stockholders (or the date immediately prior to such annual meeting if the Reporting Person's service as a director ends at such annual meeting) or (ii) on May 21, 2027, each subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:43 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000094 · wk-form4_1777326205.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,899.1714 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:15 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 1,250 | $60.17 | $75,212.50 |
DisclosureSEC source: 0001739090-26-000002 · form4-01062026_040110.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,702 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2025. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:50 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 676 | $75.55 | $51,071.80 |
DisclosureSEC source: 0001739090-25-000005 · form4-12032025_041201.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,952 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2025. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:15 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Comnmon Stock | 1,926 | $71.45 | $137,612.70 |
DisclosureSEC source: 0001739090-25-000003 · form4-11132025_041101.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,628 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 27, 2024. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:15 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Comnmon Stock | 625 | $62.52 | $39,075.00 |
DisclosureSEC source: 0001415889-25-019308 · form4-07032025_040713.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,554 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 27, 2024. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Comnmon Stock | 558 | $55.20 | $30,801.60 |
DisclosureSEC source: 0001415889-25-015576 · form4-06042025_040615.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,179 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 27, 2024. Read SEC document |
| May 20, 2025 Filed May 23, 2025 00:00 UTC | Tempus AI, Inc. TEM · Entity 1545 | GrantClass A Comnmon Stock | 1,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014306 · form4-05222025_080517.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,737 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the Issuer's 2026 annual meeting of the stockholders (or the date immediately prior to such annual meeting if the Reporting Person's service as a director ends at such annual meeting) or (ii) on May 20, 2026, each subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| April 24, 2025 Filed Apr 28, 2025 21:38 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,316 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000122 · wk-form4_1745876302.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,656.1384 Underlying: Common Stock · 1,316 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:15 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 625 | $48.12 | $30,075.00 |
DisclosureSEC source: 0001415889-25-009939 · form4-04032025_040415.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,740 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 22:30 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 900 | $50.63 | $45,567.00 |
DisclosureSEC source: 0001415889-25-008652 · form4-03192025_060301.xml · nonDerivative · entry 5 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,365 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.46 to $50.84 inclusive. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 22:30 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 3,142 | $50.04 | $157,225.68 |
DisclosureSEC source: 0001415889-25-008652 · form4-03192025_060301.xml · nonDerivative · entry 4 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,265 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.45 inclusive. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 22:30 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 1,214 | $48.90 | $59,364.60 |
DisclosureSEC source: 0001415889-25-008652 · form4-03192025_060301.xml · nonDerivative · entry 3 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,407 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.40 to $49.33 inclusive. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 22:30 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 2,046 | $48.11 | $98,433.06 |
DisclosureSEC source: 0001415889-25-008652 · form4-03192025_060301.xml · nonDerivative · entry 2 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,621 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.39 to $48.38 inclusive. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 22:30 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 2,006 | $46.67 | $93,620.02 |
DisclosureSEC source: 0001415889-25-008652 · form4-03192025_060301.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,667 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6). Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:15 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 338 | $57.52 | $19,441.76 |
DisclosureSEC source: 0001415889-25-006937 · form4-03052025_040308.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,673 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. Read SEC document |
| February 14, 2025 Filed Feb 15, 2025 00:53 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 1,320 | $90.00 | $118,800.00 |
DisclosureSEC source: 0001415889-25-004326 · form4-02152025_120208.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,011 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 23:20 UTC | Tempus AI, Inc. TEM · Entity 1545 | SaleClass A Common Stock | 1,183 | $41.81 | $49,461.23 |
DisclosureSEC source: 0001415889-24-029367 · form4-12132024_061210.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,331 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. Read SEC document |
| June 13, 2024 Filed Jun 18, 2024 01:45 UTC | Tempus AI, Inc. TEM · Entity 1545 | GrantClass A Common Stock | 38,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017305 · form4-06172024_090610.xml · nonDerivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,514 F1 · shares: Consists of previously granted restricted stock units ("RSUs") for which the liquidity event-based condition was satisfied upon the effectiveness of the registration statement on Form S-1 filed by the Issuer in connection with the Issuer's initial public offering, as well as, a grant of RSUs made in connection with the Issuer's Non-Employee Director Compensation Policy. Certain of the RSUs remain subject to service-based vesting conditions, as follows: (i) 8,750 RSUs vest in seven equal quarterly installments commencing on July 1, 2024 and (ii) 13,514 RSUs vest in 20 substantially equal quarterly installments commencing on September 13, 2024. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 21:05 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,385.697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005328 · doc4.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,081.638 Underlying: Common Stock · 1,385.697 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 27, 2023 Filed May 2, 2023 21:21 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,193.975 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005250 · doc4.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,498.858 Underlying: Common Stock · 1,193.975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:46 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002579 · doc4.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,132.765 Underlying: Common Stock · 1,175 shares Expires not disclosed F1 · security: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 22:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002220 · doc4.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,858.651 Underlying: Common Stock · 1,123 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:10 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002165 · doc4.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,662.092 Underlying: Common Stock · 1,221 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 19:55 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002424 · doc4.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,402 Underlying: Common Stock · 1,402 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.